Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
191 hedge funds and large institutions have $647M invested in Esperion Therapeutics in 2026 Q2 according to their latest regulatory filings, with 64 funds opening new positions, 46 increasing their positions, 53 reducing their positions, and 78 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
35% more capital invested
Capital invested by funds: $479M → $647M (+$168M)
11.54% more ownership
Funds ownership: 68.09% → 79.62% (+12%)
4% less call options, than puts
Call options by funds: $3.29M | Put options by funds: $3.42M
8% less funds holding
Funds holding: 207 → 191 (-16)
13% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 53
18% less first-time investments, than exits
New positions opened: 64 | Existing positions closed: 78
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$62.7M |
| 2 |
TC
Trium Capital
London,
United Kingdom
|
+$31.2M |
| 3 |
Goldman Sachs
New York
|
+$22.3M |
| 4 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$16.9M |
| 5 |
OBAM
ODDO BHF Asset Management
Paris,
France
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$38.7M |
| 2 |
TSC
Two Seas Capital
Rye,
New York
|
-$31.2M |
| 3 |
O
OrbiMed
New York
|
-$29M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$19.8M |
| 5 |
D.E. Shaw & Co
New York
|
-$17.9M |
ESPR Hedge Fund Activity: Q2 2026 in Review
191 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q2 2026, worth a combined $647M — up 35% from $479M a quarter earlier.
Sellers outnumbered buyers: 78 funds closed out of ESPR and 64 opened new positions — a net loss of 14 holders — while 53 trimmed existing stakes and 46 added.
The largest buyer was Glazer Capital LLC, opening a new position worth an estimated $62.7M. The largest seller was Wasatch Advisors, cutting an estimated $38.7M.
- 191 institutional investors held Esperion Therapeutics (ESPR) as of Q2 2026, down from 207 in Q1 2026.
- Funds reported $647M of Esperion Therapeutics stock for Q2 2026, up 35% quarter-over-quarter.
- 64 funds opened new Esperion Therapeutics positions in Q2 2026 and 78 closed out, a net change of -14 holders.
- The largest Esperion Therapeutics buyer in Q2 2026 was Glazer Capital LLC, an estimated $62.7M added.
- The largest Esperion Therapeutics seller in Q2 2026 was Wasatch Advisors, an estimated $38.7M sold.
Based on aggregated 13F filings for Q2 2026.